Results 161 to 170 of about 115,048 (305)

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu   +3 more
wiley   +1 more source

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

open access: yesBritish Journal of Haematology, EarlyView.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George   +13 more
wiley   +1 more source

Lymphocyte count and risk of chronic lymphocytic leukemia. [PDF]

open access: yesJ Natl Cancer Inst
Pahnke S   +6 more
europepmc   +1 more source

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

open access: yesBritish Journal of Haematology, EarlyView.
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup   +23 more
wiley   +1 more source

Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Chemotherapy‐induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross‐talk and restores therapeutic response, highlighting WNT inhibitors as a promising strategy to prevent relapse in ALL.
Foteini Kalampalika   +4 more
wiley   +1 more source

Hematolymphoid neoplasms involving the breast: A single institution clinicopathologic study of 59 patients. [PDF]

open access: yesAnn Hematol
Vickery J   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy